MXCT Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PIRKIMAS 136856 min ago

@ $4.78

Išleistas: 14 vas. 2024 @ 19:00

Grąža: -2.30%

Ankstesnis signalas: vas. 13 - 17:49

Ankstesnis signalas: Pardavimas

Grąža: -0.46 %

Live Chart Being Loaded With Signals

Commentary (17 geg. 2024 @ 23:00):

Stats
Šios dienos apimtis	270 413
Vidutinė apimtis	560 692
Rinkos kapitalizacija	488.22M
EPS	$0 ( 2024-05-08 )
Kita pelno data	( $0 ) 2024-08-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-13.34
ATR14	$0.00800 (0.17%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-26	Johnston John Joseph	Buy	5 000	Common Stock
2024-03-26	Johnston John Joseph	Sell	5 000	Common Stock
2024-03-26	Johnston John Joseph	Sell	5 000	Stock Option (right to buy)
2024-03-15	Ross Thomas M.	Buy	100 000	Employee Stock Option (right to buy)
2024-03-15	Ross Thomas M.	Buy	25 000	Common Stock

INSIDER POWER
40.30
Last 100 transactions
Buy: 1 609 082 \| Sell: 743 053

Tūris Koreliacija

Ilgas: -0.32 (neutral)

Trumpas: -0.57 (weak negative)

Signal:(26.684) Neutral

MaxCyte, Inc. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

MaxCyte, Inc. Koreliacija - Valiuta/Žaliavos

-0.15
( neutral )

0.19
( neutral )

0.00
( neutral )

-0.08
( neutral )

0.00
( neutral )

-0.30
( neutral )

MaxCyte, Inc. Finansinės ataskaitos

Annual	2023
Pajamos:	$41.29M
Bruto pelnas:	$32.56M (78.86 %)
EPS:	$-0.370

FY	2023
Pajamos:	$41.29M
Bruto pelnas:	$32.56M (78.86 %)
EPS:	$-0.370

FY	2022
Pajamos:	$44.26M
Bruto pelnas:	$39.16M (88.48 %)
EPS:	$-0.190

FY	2021
Pajamos:	$33.89M
Bruto pelnas:	$30.25M (89.24 %)
EPS:	$-0.210

Financial Reports:

No articles found.

MaxCyte, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

MaxCyte, Inc.

MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.